Liminatus Pharma believes it meets Nasdaq equity minimum after InnocsAI merger

Liminatus Pharma, Inc.

Company believes stockholders' equity now exceeds $2.5 million following merger with InnocsAI LLC.
Awaiting Nasdaq compliance determination; Nasdaq will continue to monitor compliance.
If next periodic report does not show compliance, Company may face future delisting.
Merger with InnocsAI LLC previously announced; no further deal terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.